Portfoliotracker

MoonLake Immunotherapeutics

MLTX · NASDAQCM · Healthcare Biotechnology 0/100 E

11,73 $
▼ −0,77 (−6,16 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:44
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap1,00 mld. $ P/E– Forward P/E-3,6 P/S– P/B2,6 EV/EBITDA– Dividend yield– FCF yield-24,37 % EPS-3,66 $ Net margin0,0 % Return on equity-81,5 % Beta1,13 Debt / equity0,27
52-week range 9,46 to 23,29
3-month average volume1,6 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Employees
130
Country
Switzerland
Fiscal year end
31. 12.
Data since
20. 10. 2020

Explore further

Similar companies IMVTVERAJANXKYMRPCVX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account